The three main tumor subtypes of BC, characterized by ER or PR expression and amplification of the ERBB2 gene, have different risk characteristics and treatment strategies, with the optimal treatment for each patient depending on the tumor subtype, anatomic tumor stage, and patient preference (11, 21–25). Here, PGR is linked to neoplasm.